



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/642,272 Confirmation No.: 3248
Applicant : Fumiyuki HATTORI, et al.
Filed : August 18, 2003
Title : THERAPEUTIC METHODS AND AGENTS FOR DISEASES
ASSOCIATED WITH DECREASED EXPRESSION OF AOP-1
GENE OR AOP-1
TC/Art Unit : 1632
Examiner: : Marcia Noble STEPHENS, Ph.D.
Docket No. : 58777.000012
Customer No. : 21967

Mail Stop Box Sequence

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821 and 1.825

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.821 and 1.825, Applicants submit herewith a substitute paper copy of "Sequence Listing," totaling fourteen (14) pages. Applicants submit herewith a substitute computer readable copy of the "Sequence Listing" on a CD-ROM in ASCII format as required by 37 C.F.R. §§ 1.821(e) and 1.825(a).

In accordance with the provisions of 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the "Sequence Listing" submitted herewith are identical.

In accordance with the provisions of 37 C.F.R. § 1.825(a), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the substitute "Sequence Listing" submitted herewith do not constitute new matter. The amendments included herein add two (2) new SEQ ID NOs for sequences present in the specification at page 37, line 1, now designated SEQ ID NOs: 31 and 32. The undersigned hereby states that the amendments provided herein have support in the application as filed. Also, the amendment to the paper copy of the "Sequence Listing," in accordance with

1.821(a) is accompanied by a substitute copy of the computer readable form including all previously submitted data with the amendment incorporated therein.

Applicants respectfully request entry of this sequence listing and submit that the sequence listing and amendment do not constitute new matter.

CONCLUSION


It is believed that no additional fees are required with this submission. However, in the event that additional fees are deemed necessary, to maintain the present application pending, or in the event of any variance between the amount enclosed and the fees determined by the U.S. Patent and Trademark Office, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206.**

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: February 9, 2007

By:


Robert M. Schulman
Registration No. 31,196

Christopher J. Nichols, Ph.D.
Registration No. 55,984

HUNTON & WILLIAMS LLP
Litigation, Intellectual Property & Antitrust
1900 K Street, N.W. Suite 1200
Washington, D.C. 20006
Telephone (202) 955-1500
Fax: (202) 778-2201

RMS/CJN:cdh